The phencyclidine (PCP) analog N-[1-(2-benzo(B)thiophenyl) cyclohexyl]piperidine shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine and MK-801

W Koek, FC Colpaert, JH Woods and JM Kamenka

Neurobiology Division, FONDAX-Groupe de Recherche Servier, Puteaux, France.

Phencyclidine (PCP) inhibits dopamine (DA) uptake and acts as a noncompetitive N-methyl-D-aspartate antagonist by binding to PCP receptors. The PCP analog N-[1-(2-benzo(b)thiophenyl) cyclohexyl]piperidine (BTCP, GK13) is a potent DA uptake inhibitor, but has low affinity for PCP receptors. The behavioral effects of BTCP were compared with those of PCP, ketamine, MK-801 and cocaine. In mice, BTCP, like cocaine, produced locomotion, sniffing and gnawing; haloperidol blocked these effects. PCP, ketamine and MK-801 produced locomotion, sniffing, swaying and falling. PCP, ketamine and MK-801 produced generalization in rats discriminating either cocaine, PCP or MK-801 from saline. Like cocaine, BTCP produced generalization in cocaine-discriminating rats only; haloperidol partially antagonized this effect. In pigeons, PCP-like catalepsy was produced by ketamine and MK-801, but not by BTCP. N-methyl-D-aspartate-induced convulsions in mice were antagonized by PCP, ketamine and MK-801, but not by BTCP or cocaine. Thus, BTCP shared only cocaine-like behavioral effects with PCP, ketamine and MK-801. A DA antagonist reduced the effects of BTCP. Therefore, the cocaine-like behavioral effects of BTCP may be mediated primarily by DA uptake mechanisms. However, PCP receptors, but not DA uptake mechanisms, may mediate the cocaine-like behavioral effects of PCP, ketamine and MK-801, because their order of potency in producing these effects (MK-801 greater than PCP greater than ketamine) is consistent with their potency order at PCP receptors, but not at DA uptake sites.

Volume 250, Issue 3, pp. 1019-1027, 09/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. H. Krystal, I. L. Petrakis, E. Webb, N. L. Cooney, L. P. Karper, S. Namanworth, P. Stetson, L. A. Trevisan, and D. S. Charney Dose-Related Ethanol-like Effects of the NMDA Antagonist, Ketamine, in Recently Detoxified Alcoholics Arch Gen Psychiatry, April 1, 1998; 55(4): 354 - 360. [Abstract] [Full Text] [PDF]

				K. M. Kantak, M. A. Edwards, K. M. Wilcox, and E. Kitchel Discriminative Stimulus Effects of Magnesium Chloride: Substitution Studies with Monoamine Uptake Inhibitors and N-Methyl-D-Aspartate Antagonists J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 200 - 206. [Abstract] [Full Text]

				H.S. Garcha and I.P. Stolerman Discriminative stimulus effects of the nicotine antagonist mecamylamine in rats J Psychopharmacol, January 1, 1993; 7(1_suppl): 43 - 51. [Abstract] [PDF]